[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
June 11, 2014

Revolution to a New Standard Treatment of Diabetic Macular Edema

Author Affiliations
  • 1Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 2Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 3Jaeb Center for Health Research, Tampa, Florida
JAMA. 2014;311(22):2269-2270. doi:10.1001/jama.2014.2536

The prevalence of diabetes mellitus worldwide is increasing, in part due to an obesity epidemic. Thus, prevention and treatment of vision loss from diabetic retinopathy, including proliferative diabetic retinopathy and diabetic macular edema (DME), has become more important.1 Diabetic macular edema, a swelling of the central part of the macula (Figure), affects approximately 746 000 adults aged 40 years or older in the United States (approximately 4% with diabetes develop DME).2

First Page Preview View Large
First page PDF preview
First page PDF preview
×